Who are IMOVAX Polio®'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imovax-polio.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IMOVAX Polio® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IMOVAX Polio® (IMOVAX Polio®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated poliovirus vaccine (IPV). Area: Immunology / Infectious Disease.

phase 3 Inactivated poliovirus vaccine (IPV) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

IMOVAX Polio® (IMOVAX Polio®) — GlaxoSmithKline. IMOVAX Polio is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, providing protection against poliomyelitis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IMOVAX Polio® TARGET	IMOVAX Polio®	GlaxoSmithKline	phase 3	Inactivated poliovirus vaccine (IPV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated poliovirus vaccine (IPV) class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IMOVAX Polio® — Competitive Intelligence Brief. https://druglandscape.com/ci/imovax-polio. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing